There are 3 companies in the S&P 500 & NASDAQ 100 that flashed SMAC Sell Signals today: $ABBV, $ESS, $INTU
January 14, 2026 at 11:02 PM
There are 3 companies in the S&P 500 & NASDAQ 100 that flashed SMAC Sell Signals today: $ABBV, $ESS, $INTU
AbbVie dodges tariffs while Netflix sharpens its earnings pitch; RTX plays defense in the spotlight. $ABBV $NFLX $RTX #MarketTrends #Earnings #StockWatch #FinanceNews
Tariffs, Earnings and Defense Spending: Where AbbVie, Netflix and RTX Stand Now
click here to read more
tradeengine.io
January 14, 2026 at 2:00 PM
AbbVie dodges tariffs while Netflix sharpens its earnings pitch; RTX plays defense in the spotlight. $ABBV $NFLX $RTX #MarketTrends #Earnings #StockWatch #FinanceNews
This $ABBV agreement with the Trump Admin is amusing. They agree to invest $100bn in R&D over 10 years (their current rate) and provide low prices to Medicaid (which they are required to under law). In exchange 3 yrs of tariff and future price mandate relief. Should call it status quo agreement
January 13, 2026 at 1:00 PM
This $ABBV agreement with the Trump Admin is amusing. They agree to invest $100bn in R&D over 10 years (their current rate) and provide low prices to Medicaid (which they are required to under law). In exchange 3 yrs of tariff and future price mandate relief. Should call it status quo agreement
Buy $ABBV (ABBV.N) @ 23:31:02
January 12, 2026 at 11:31 PM
Buy $ABBV (ABBV.N) @ 23:31:02
AbbVie $ABBV and RemeGen announce exclusive ex China licensing agreement to develop a PD-1/VEGF bispecific antibody for advanced solid tumors
$650M upfront and up to $4.95B total deal
#JPM26 news is cautiously warming up
news.abbvie.com/2026-01-12-A...
$650M upfront and up to $4.95B total deal
#JPM26 news is cautiously warming up
news.abbvie.com/2026-01-12-A...
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/...
news.abbvie.com
January 12, 2026 at 2:56 PM
AbbVie $ABBV and RemeGen announce exclusive ex China licensing agreement to develop a PD-1/VEGF bispecific antibody for advanced solid tumors
$650M upfront and up to $4.95B total deal
#JPM26 news is cautiously warming up
news.abbvie.com/2026-01-12-A...
$650M upfront and up to $4.95B total deal
#JPM26 news is cautiously warming up
news.abbvie.com/2026-01-12-A...
#WST #ABBV West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
https://www.stocktitan.net/news/WST/west-signs-agreement-to-sell-the-manufacturing-and-supply-rights-for-a3faxvlp7288.html
https://www.stocktitan.net/news/WST/west-signs-agreement-to-sell-the-manufacturing-and-supply-rights-for-a3faxvlp7288.html
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.
www.stocktitan.net
January 12, 2026 at 11:00 AM
#WST #ABBV West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
https://www.stocktitan.net/news/WST/west-signs-agreement-to-sell-the-manufacturing-and-supply-rights-for-a3faxvlp7288.html
https://www.stocktitan.net/news/WST/west-signs-agreement-to-sell-the-manufacturing-and-supply-rights-for-a3faxvlp7288.html
#WST #ABBV AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
https://www.stocktitan.net/news/WST/abb-vie-to-acquire-arizona-manufacturing-facility-further-8ug3s3g2d07r.html
https://www.stocktitan.net/news/WST/abb-vie-to-acquire-arizona-manufacturing-facility-further-8ug3s3g2d07r.html
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.
www.stocktitan.net
January 12, 2026 at 11:00 AM
#WST #ABBV AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
https://www.stocktitan.net/news/WST/abb-vie-to-acquire-arizona-manufacturing-facility-further-8ug3s3g2d07r.html
https://www.stocktitan.net/news/WST/abb-vie-to-acquire-arizona-manufacturing-facility-further-8ug3s3g2d07r.html
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research | BeyondLINK
beyondlink.live
January 12, 2026 at 4:05 AM
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research | BeyondLINK
beyondlink.live
January 12, 2026 at 4:05 AM
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research
#BiotechHangout Sam Fazeli, Paul Matteis, Brian Skorney, Tess Cameron on market sentiment: $XBI & M&A, politics: peds vaccine update, deals: fundraising & IPO filing, $AZN/Jacobio, $ABBV/$RVMD, data: $CRNX, $ZBIO, $RARE, $NVO, $ARWR, $SNY, $NMRA, $GHRS, $ALMS, $DRUG & OL epilepsy data bit.ly/49elSld
January 9, 2026 at 2:17 PM
#BiotechHangout Sam Fazeli, Paul Matteis, Brian Skorney, Tess Cameron on market sentiment: $XBI & M&A, politics: peds vaccine update, deals: fundraising & IPO filing, $AZN/Jacobio, $ABBV/$RVMD, data: $CRNX, $ZBIO, $RARE, $NVO, $ARWR, $SNY, $NMRA, $GHRS, $ALMS, $DRUG & OL epilepsy data bit.ly/49elSld
$ABBV $ABSI $CTNM $EXEL $ICLR $LOGI $MQ $NBIX $SGML $TOST $VALE $VSTS $XPO -- THE WSJ
January 8, 2026 at 3:33 PM
$ABBV $ABSI $CTNM $EXEL $ICLR $LOGI $MQ $NBIX $SGML $TOST $VALE $VSTS $XPO -- THE WSJ
Early👀1-8-26
Spu-12, Naz-68, DJI-183
10-yr 4.17%, JGB10 2.08%
Crude+1.5%, Gold-.75%, SLV-4%
BTC-1.3%
DN: AA, ABBV, ABSI, AMH, BALL,
BWA, CLVT, CTNM, CWAN, DRI, EEFT, EXEL,
EXR, IAFNF, ICLR, INTU, INVH, JBHT,
MQ, NBIX, NKE, OS, PCH, PLD, R, RCUS, SAIA, TOST, TRV,
TSCO, UPS, VALE, VTYX, WAB, XPO
Spu-12, Naz-68, DJI-183
10-yr 4.17%, JGB10 2.08%
Crude+1.5%, Gold-.75%, SLV-4%
BTC-1.3%
DN: AA, ABBV, ABSI, AMH, BALL,
BWA, CLVT, CTNM, CWAN, DRI, EEFT, EXEL,
EXR, IAFNF, ICLR, INTU, INVH, JBHT,
MQ, NBIX, NKE, OS, PCH, PLD, R, RCUS, SAIA, TOST, TRV,
TSCO, UPS, VALE, VTYX, WAB, XPO
January 8, 2026 at 1:20 PM
Early👀1-8-26
Spu-12, Naz-68, DJI-183
10-yr 4.17%, JGB10 2.08%
Crude+1.5%, Gold-.75%, SLV-4%
BTC-1.3%
DN: AA, ABBV, ABSI, AMH, BALL,
BWA, CLVT, CTNM, CWAN, DRI, EEFT, EXEL,
EXR, IAFNF, ICLR, INTU, INVH, JBHT,
MQ, NBIX, NKE, OS, PCH, PLD, R, RCUS, SAIA, TOST, TRV,
TSCO, UPS, VALE, VTYX, WAB, XPO
Spu-12, Naz-68, DJI-183
10-yr 4.17%, JGB10 2.08%
Crude+1.5%, Gold-.75%, SLV-4%
BTC-1.3%
DN: AA, ABBV, ABSI, AMH, BALL,
BWA, CLVT, CTNM, CWAN, DRI, EEFT, EXEL,
EXR, IAFNF, ICLR, INTU, INVH, JBHT,
MQ, NBIX, NKE, OS, PCH, PLD, R, RCUS, SAIA, TOST, TRV,
TSCO, UPS, VALE, VTYX, WAB, XPO
AbbVie $ABBV Wolfe Research Downgrades from Outperform to Peer Perform.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
January 8, 2026 at 12:30 PM
AbbVie $ABBV Wolfe Research Downgrades from Outperform to Peer Perform.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
📊 after a reported +22% pop; narrative split on strategic fit in solid tumors vs overpay/competition in RAS oncology, with $ABBV leverage (~$70B debt) noted despite strong FCF.
Watch for confirmation/termination headlines into #JPM26 positioning; absent clarity, expect continued rumor-driven
Watch for confirmation/termination headlines into #JPM26 positioning; absent clarity, expect continued rumor-driven
January 8, 2026 at 11:36 AM
📊 after a reported +22% pop; narrative split on strategic fit in solid tumors vs overpay/competition in RAS oncology, with $ABBV leverage (~$70B debt) noted despite strong FCF.
Watch for confirmation/termination headlines into #JPM26 positioning; absent clarity, expect continued rumor-driven
Watch for confirmation/termination headlines into #JPM26 positioning; absent clarity, expect continued rumor-driven
📊 🎯 $ABBV–$RVMD headline whipsaw is driving event-risk volatility: WSJ “advanced talks” chatter vs a Bloomberg-cited AbbVie spokesperson denial keeps deal odds—and biotech risk appetite—binary.
Rumor tape frames valuation “around/over $20B+” vs $RVMD ~$16B market cap (also cited near ~$19B)
Rumor tape frames valuation “around/over $20B+” vs $RVMD ~$16B market cap (also cited near ~$19B)
January 8, 2026 at 11:36 AM
📊 🎯 $ABBV–$RVMD headline whipsaw is driving event-risk volatility: WSJ “advanced talks” chatter vs a Bloomberg-cited AbbVie spokesperson denial keeps deal odds—and biotech risk appetite—binary.
Rumor tape frames valuation “around/over $20B+” vs $RVMD ~$16B market cap (also cited near ~$19B)
Rumor tape frames valuation “around/over $20B+” vs $RVMD ~$16B market cap (also cited near ~$19B)
AbbVie denies takeout talks for Revolution Medicines $ABBV $RVMD firstwordpharma.com/story/7047880
January 7, 2026 at 11:47 PM
AbbVie denies takeout talks for Revolution Medicines $ABBV $RVMD firstwordpharma.com/story/7047880
BREAKING: $ABBV says it is not in discussions with $RVMD.
$RVMD +28.6%, $ERAS +42.4%, $ABBV +4.25% [AbbVie is negotiating to buy cancer-drug maker Revolution Medicines in a potential $20+ billion deal to offset Humira patent losses and expand its oncology portfolio.] notreload.xyz/abbvie-to-ac...
AbbVie to Acquire Revolution Medicines for $20B
AbbVie is negotiating to buy cancer-drug maker Revolution Medicines in a potential $20+ billion deal to offset Humira patent losses and expand its oncology portfolio.
notreload.xyz
January 7, 2026 at 9:10 PM
BREAKING: $ABBV says it is not in discussions with $RVMD.
$RVMD +28.6%, $ERAS +42.4%, $ABBV +4.25% [AbbVie is negotiating to buy cancer-drug maker Revolution Medicines in a potential $20+ billion deal to offset Humira patent losses and expand its oncology portfolio.] notreload.xyz/abbvie-to-ac...
AbbVie to Acquire Revolution Medicines for $20B
AbbVie is negotiating to buy cancer-drug maker Revolution Medicines in a potential $20+ billion deal to offset Humira patent losses and expand its oncology portfolio.
notreload.xyz
January 7, 2026 at 9:04 PM
$RVMD +28.6%, $ERAS +42.4%, $ABBV +4.25% [AbbVie is negotiating to buy cancer-drug maker Revolution Medicines in a potential $20+ billion deal to offset Humira patent losses and expand its oncology portfolio.] notreload.xyz/abbvie-to-ac...
Some Big Tech and Health Care doing well today (MSFT, GOOGL, NVDA, LLY, ABBV), rest of the market is mixed to lower, large-caps over small-caps.
Crude oil is down again and now lower than it was before the US attacked Venezuela.
And S&P 500 Energy sector down again, also well below Friday's close.
Crude oil is down again and now lower than it was before the US attacked Venezuela.
And S&P 500 Energy sector down again, also well below Friday's close.
January 7, 2026 at 7:01 PM
Some Big Tech and Health Care doing well today (MSFT, GOOGL, NVDA, LLY, ABBV), rest of the market is mixed to lower, large-caps over small-caps.
Crude oil is down again and now lower than it was before the US attacked Venezuela.
And S&P 500 Energy sector down again, also well below Friday's close.
Crude oil is down again and now lower than it was before the US attacked Venezuela.
And S&P 500 Energy sector down again, also well below Friday's close.
Today’s stock stage features AbbVie, IBM, Netflix, and UnitedHealth—bring your popcorn and your research. $ABBV $IBM $NFLX $UNH #Stocks #Markets #Finance #Trading
Four Stocks to Watch Today: AbbVie’s Canadian Win, IBM Upgrade, Netflix Volatility and UnitedHealth’s Value Test
click here to read more
tradeengine.io
January 7, 2026 at 2:00 PM
Today’s stock stage features AbbVie, IBM, Netflix, and UnitedHealth—bring your popcorn and your research. $ABBV $IBM $NFLX $UNH #Stocks #Markets #Finance #Trading
🚨 Dark Pool Alert: $ABBV
• Quantity: 2.13M shares
• Price: $223.93
• Total: $477.44M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
• Quantity: 2.13M shares
• Price: $223.93
• Total: $477.44M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
January 6, 2026 at 9:21 PM
🚨 Dark Pool Alert: $ABBV
• Quantity: 2.13M shares
• Price: $223.93
• Total: $477.44M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
• Quantity: 2.13M shares
• Price: $223.93
• Total: $477.44M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
🚨 Dark Pool Alert: $ABBV
• Quantity: 1.22M shares
• Price: $220.18
• Total: $269.1M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
• Quantity: 1.22M shares
• Price: $220.18
• Total: $269.1M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
January 5, 2026 at 11:15 PM
🚨 Dark Pool Alert: $ABBV
• Quantity: 1.22M shares
• Price: $220.18
• Total: $269.1M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
• Quantity: 1.22M shares
• Price: $220.18
• Total: $269.1M
Large institutional order detected away from public markets.
Track more: stocknear.com/dark-pool-flow
There are 5 companies in the S&P 500 & NASDAQ 100 that flashed SMAC Sell Signals today: $ABBV, $CDNS, $IDXX, $NTAP, $MRVL
January 5, 2026 at 11:03 PM
There are 5 companies in the S&P 500 & NASDAQ 100 that flashed SMAC Sell Signals today: $ABBV, $CDNS, $IDXX, $NTAP, $MRVL